Abstract
Le Centre Fédéral d'Expertise des Soins de Santé (KCE) a évalué différentes stratégies de vaccination antigrippale afin de déterminer celles qui génèreraient les plus grands bénéfices en termes de santé par euro dépensé. Des chercheurs de l'Université d'Anvers et de l'Université d’Hasselt ont modélisé plus de 5600 scénarios potentiels de vaccination. La vaccination universelle des enfants contre la grippe pourrait présenter un rapport coût-efficacité comparable à celui d’autres vaccins récemment introduits dans le calendrier vaccinal des enfants, pour autant que le coût de la vaccination puisse être réduit d’au moins 25%. Une telle diminution de coût pourrait être obtenue en administrant le vaccin par les services de santé scolaire ou par l’ONE, et en réduisant le prix des vaccins. Une augmentation de la vaccination des adultes de plus de 50 ans réduirait de manière significative le nombre d'hospitalisations et de décès liés à la grippe, mais entraînerait un coût élevé étant donné qu’il s’agit d’un très grand groupe.
Introduction
This report, produced by the Belgian Health Care Knowledge Centre (KCE) in 2013, provides a rigorous health technology assessment (HTA) of seasonal influenza vaccination strategies. By modeling over 5,600 scenarios, researchers from the Universities of Antwerp and Hasselt explored whether Belgium should shift its priority from high-risk adults to universal childhood vaccination. The study aims to provide evidence-based guidance for optimizing the Belgian healthcare budget while maximizing population health gains.
What Problem Does This Paper Address?
Seasonal influenza is a significant public health burden, causing substantial morbidity and mortality, particularly among the elderly and those with underlying conditions. While Belgium traditionally recommends vaccination for the 50+ population, pregnant women, and healthcare workers, children are known to be the primary drivers of viral transmission due to their high contact rates and prolonged viral shedding.
The authors tackle a complex optimization problem: Given a limited healthcare budget, which combination of age groups and risk categories should be prioritized to maximize health gains (measured in Quality-Adjusted Life Years, or QALYs) per euro spent? They specifically investigate if the "indirect protection" (herd immunity) generated by vaccinating children offers a better return on investment than current strategies focused solely on direct protection of the vulnerable.
Methods
The researchers employed two distinct modeling approaches to capture the complexities of viral spread and economic impact:
- Dynamic Transmission Model (SEIRS): To evaluate the general population, they developed a compartmental model (Susceptible-Exposed-Infectious-Recovered-Susceptible) that accounts for vaccination. Unlike static models, this dynamic approach captures how vaccinating one person reduces the risk for others. The model was stratified by age and calibrated using Belgian-specific social contact data.
- Static Models: For smaller, specific target groups (pregnant women, healthcare workers, and those with comorbidities), static models were used. These assume a fixed risk of infection, as vaccinating these smaller cohorts is unlikely to fundamentally shift population-wide transmission dynamics.
- Economic Analysis: The primary metric was the Incremental Cost-Effectiveness Ratio (ICER). The authors compared scenarios against the 2008 "current situation" and utilized probabilistic sensitivity analysis (10,000 simulations per scenario) to account for the inherent variability of flu seasons.
Key Insights and Ideas
La vaccination des enfants est un levier clé pour réduire la transmission communautaire. Source, p. 1
- The "25% Threshold" for Children: Universal childhood vaccination (ages 2–17) reaches an economic "sweet spot" (ICER < €30,000/QALY) only if the cost of administration is lowered. This suggests moving away from individual GP visits toward high-volume, school-based vaccination programs or bulk purchasing (tenders).
- Indirect Protection has Limits: While vaccinating 80% of children provides significant herd immunity, the model shows this protection is too limited to replace the vaccination of high-risk adults. Direct protection of the vulnerable remains the most reliable strategy for preventing severe outcomes.
- The 75+ Priority: Increasing coverage among those aged 75 and older remains one of the most cost-effective interventions available, regardless of what is done with other age groups.
- Ethical Trade-offs: One of the most "cost-effective" theoretical moves is to stop vaccinating healthy adults aged 18–49 to save money. However, the authors note this would increase morbidity in that group and could be considered unethical.
Key Results
- Clinical Impact: The most effective clinical strategy (80% child coverage plus increased 50+ coverage) could reduce flu-related hospitalizations and deaths by approximately 40%.
- Cost-Effectiveness: Universal childhood vaccination scenarios yielded median ICERs between €40,000 and €45,000 per QALY under baseline assumptions, which is higher than many current pediatric programs unless administrative costs are cut.
- High-Risk Groups: Vaccinating pregnant women and healthcare workers is highly cost-effective, especially if the vaccine is administered during routine visits (zero additional administration cost), resulting in ICERs as low as <€7,000/QALY.
Limitations and Future Work
The study acknowledges several limitations. The model used a single generic influenza strain, failing to distinguish between the different dynamics of Influenza A and B. Furthermore, the speed at which vaccine-induced immunity wanes is a major source of uncertainty; the authors assumed a rapid decline (average 1.68 years), which makes childhood vaccination look less favorable than a "slow decline" scenario.
Finally, the study adopted a healthcare payer perspective and did not include "indirect costs" like productivity loss from sick days. Including these would likely make all vaccination strategies appear much more attractive. Future research should also consider the cost-effectiveness of quadrivalent vaccines, which would need to be priced competitively to maintain the same cost-effectiveness profile as trivalent versions.
Summary updated